Intellia slashes workforce by 27% to focus on late stage CRISPR candidates
CRISPR biotech Intellia Therapeutics has announced plans to reduce its workforce by 27% and halt early-stage R&D programmes as it…
All articles by Jenna Philpott
Jenna Philpott
Jenna Philpott is a healthcare and pharmaceutical reporter. Coming from a scientific background, Jenna has expertise in biochemistry, genetics and cancer science. Jenna previously wrote freelance articles focused on oncology and healthcare.
-
-
Vertex and Orna sign partnership to improve efficiencies of gene therapies
Vertex Pharmaceuticals and Orna Therapeutics have announced a three-year collaboration to develop next-generation gene therapies for sickle cell disease (SCD)…
-
Acelyrin stock plunges after positive Phase II data readout in thyroid eye disease
US-based Acelyrin reported positive Phase II data for its monoclonal antibody lonigutamab in thyroid eye disease (TED), but was met…
-
Sangamo’s stock sinks 50% as Pfizer halts haemophilia A gene therapy partnership
Sangamo Therapeutics’ stock has plummeted by 50% in premarket trading after Pfizer ended the companies’ partnership to co-develop a gene…
-
Intellia’s gene editing therapy shows early potential in rare heart condition
Intellia Therapeutics has announced early-stage clinical data suggesting that its investigational gene editing treatment may stabilise or improve outcomes for…
-
How decentralisation can fill the gaps in Alzheimer’s research
In a new era of Alzheimer’s disease research, the emergence of blockbuster therapies like Eli Lilly’s Kisunla (donanemab) and Eisai…
-
Exact Sciences showcases early cancer detection test data at AACR meeting
Exact Sciences has unveiled new findings from a case-control study demonstrating the potential of its advanced multi-biomarker class approach to…
-
Adaptimmune nears second sarcoma approval as Phase II trial hits endpoints
Adaptimmune’s pivotal Phase II trial of its investigational T cell therapy lete-cel has met its primary endpoint, with the company…
-
Putting the DACH region on the map for clinical trials
Amid tightening EU regulations, a growing emphasis on digitalisation and artificial intelligence (AI), and complex questions around ethics, the viability…
-
Syndax’s stock sinks by 25% despite AML trial meeting primary endpoint
Syndax Pharmaceuticals has announced that its Phase II trial of revumenib achieved its primary endpoint in certain patients with relapsed…